IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shafiee, A.
Right arrow Articles by Blake, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shafiee, A.
Right arrow Articles by Blake, D. A.
(Investigative Ophthalmology and Visual Science. 2000;41:2378-2388.)
© 2000 by The Association for Research in Vision and Ophthalmology, Inc.

Inhibition of Retinal Angiogenesis by Peptides Derived from Thrombospondin-1

Afshin Shafiee1,2, John S. Penn3, Henry C. Krutzsch4, John K. Inman4, David D. Roberts4 and Diane A. Blake1

1 From the Department of Ophthalmology, Tulane University School of Medicine, New Orleans, Louisiana; the 2 Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee; and the 3 Laboratory of Pathology, National Cancer Institute and National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.


   Abstract
Top
 Abstract
Introduction
 Methods
 Results
 Discussion
 References
 
PURPOSE. Thrombospondin (TSP)-1 is a tumor suppressor with activity that is associated with its ability to inhibit neovascularization. Previous studies have mapped this antiangiogenic activity to the type 1 repeats and the amino-terminal portion of the molecule within the procollagen-like domain. The present study was performed to investigate the ability of TSP-1 and peptides derived from the type 1 repeats to inhibit retinal angiogenesis.

METHODS. TSP-1 and peptides with tryptophan-rich, heparin-binding sequences and transforming growth factor (TGF)-ß1 activation sequences were evaluated in two models of retinal angiogenesis: a retinal explant assay and a rat model of retinopathy of prematurity (ROP).

RESULTS. Platelet-derived TSP-1 inhibited angiogenesis in both experimental models. Peptides from the native TSP-1 sequence, which contained both the tryptophan-rich repeat and the TGF-ß1 activation sequence, were the most potent inhibitors of endothelial cell outgrowth in the retinal explant assay. In contrast, a peptide containing only the tryptophan-rich, heparin-binding sequence was most active in inhibiting neovascular disease in the rat ROP model.

CONCLUSIONS. These results indicate that the type 1 repeats of TSP-1 contain two subdomains that may independently influence the process of neovascularization, and that peptides derived from these type 1 repeats may be promising pharmacologic agents for treatment of retinal angiogenesis.


   Introduction
Top
 Abstract
 Introduction
Methods
 Results
 Discussion
 References
 
Neovascular diseases of the retina collectively constitute the leading cause of blindness in developed countries.1 2 At present, retinal laser photocoagulation appears to be the most effective treatment for retinal neovascularization. However, this procedure can destroy postmitotic retinal neurons and permanently affect visual function. Pharmacologic agent(s) that inhibit angiogenesis without destroying retinal tissue could lead to new treatments for this constellation of diseases. Because angiogenesis is a multistep process regulated by an array of growth factors and extracellular matrix molecules (for reviews, see References 3–5) there are potentially many ways to interfere with its progression. Recently, a number of investigators have partially inhibited retinal and iris angiogenesis in vivo using monoclonal antibodies,6 receptor-binding chimeric proteins,7 and antisense oligonucleotides to vascular endothelial growth factor (VEGF),8 an endothelium-specific growth factor.

Thrombospondin (TSP)-1 is an extracellular matrix glycoprotein that has been shown to be both anti- and proangiogenic in various angiogenesis models.9 10 11 12 13 14 These conflicting results may be due to the complex structure of the protein and its ability to bind to a number of receptors on the same cell type (Fig. 1 ; for a review, see Reference 15). The regions of TSP-1 responsible for its antiangiogenic activity have been mapped to the procollagen-like domain and to the type I repeats.16 The antiangiogenic activity of these regions has been variously attributed to activation of latent transforming growth factor (TGF)-ß1,17 competition for fibroblast growth factor (FGF)-2 binding to the endothelial cell surface,18 19 interaction with heparan sulfate proteoglycans,19 20 and binding to CD36, a receptor for TSP-1.21 The RGD and VVM sequences of TSP-1 also interact directly and indirectly with integrins, including both the {alpha}vß3 and {alpha}vß5 integrins.22 Ligation of these integrins has been shown to prevent endothelial apoptosis during angiogenesis.23 24



View larger version (17K):
[in this window]
[in a new window]
  		Figure 1. Structural domains of TSP-1. Diagram shows a single subunit of the TSP-1 trimer, which is covalently assembled through disulfide bonds (S). Selected peptide sequences with reported functional activities are positioned as indicated. The antiangiogenic activities of the boxed sequences (from peptide 246) were investigated in this study.

 
The therapeutic potential of the intact TSP-1 molecule is limited by its size (a trimer of 450 kDa) and its multiple biological activities; however, small peptides derived from it should provide a reasonable alternative for preventing the pathologic growth of new blood vessels. Heparin-binding peptides derived from the type 1 repeats of TSP-125 have been shown to antagonize FGF-2 binding to endothelial cell surfaces through binding to heparan sulfate and proteoglycans,19 to inhibit endothelial cell chemotaxis to FGF-2,19 and to induce apoptosis of endothelial cells.26 Stable synthetic peptide analogues of these peptides suppress breast carcinoma growth in a dose-dependent manner.27 The present study was undertaken to evaluate the ability of TSP-1 and different regions in the TSP-1 type 1 repeats to inhibit angiogenesis in two ocular models of angiogenesis: a retinal explant assay and a rat model of ROP. We demonstrated that a small peptide from the type 1 repeats contained two active regions and that the activity of these two regions could vary, depending on the model system used to study the angiogenic process.


   Methods
Top
 Abstract
 Introduction
 Methods
Results
 Discussion
 References
 
Platelet-derived TSP-1 and rat tail type I collagen were purchased from Sigma (St. Louis, MO). Glucose-free Glasgow minimum essential medium (10x; GMEM) and HEPES buffer solution (1 M) were purchased from Gibco (Grand Island, NY). Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT). The peptides used in this study (Table 1) were synthesized, purified, and analyzed as described elsewhere.25 27 Peptide 246 was derived from the native sequence of TSP-1,25 and peptides 450 and 388 were controls prepared by systematically substituting alanine for specific amino acids known to be required for heparin binding or the activation of latent TGF-ß1.17 20 Such substituted controls are usually better than scrambled peptide controls, because they retain the same secondary structure as the native sequence. D-Reverse peptide analogues were used in some experiments because of their superior resistance to most proteases. These D-reverse peptides have been shown to be active, and the stereochemical requirements for their activities have been published.27 For intravitreal injections, D-reverse analogues were covalently conjugated to polysucrose of molecular weight 70,000 to prevent rapid vitreous clearance.27 Peptides used for biological assays were purified by dialysis using Spectrapor 500-Mr cutoff membranes (Spectrum, Rancho Dominquez, CA), then lyophilized and stored at -20°C. Immediately before use, the peptides were dissolved in purified water or normal saline and filter sterilized.


View this table:
[in this window]
[in a new window]
  		Table 1. Peptides

 
Bovine Retinal Explant Assay
Vascular endothelial outgrowth from retinal discs was assessed using modifications of a previously published procedure.28 Bovine eyes were processed within 2 hours of death. Excess tissue was removed and the orbits covered with gauze saturated with gentamicin (100 µg/ml in water) for 15 minutes. Under sterile conditions by using a pair of blunt curved forceps, retinas were gently peeled off the choroid, cut at the disc, and floated in a 100 x 15-mm tissue culture dish containing 1x GMEM. Retinal discs from three to four retinas were cut from the peripheral retina with a 3-mm trephine and randomized. For the preparation of collagen gels, all procedures were performed on ice. Collagen (3.3 ml) was made up in 0.012 N HCl at a concentration of 3 mg/ml and neutralized by the addition of 1 N sodium hydroxide (40 µl). HEPES buffer solution (40 µl) and 10x GMEM (0.5 ml) were added to restore physiologic ionic strength. At this point 1x GMEM containing 10% FBS and varying concentrations of the test peptide (in 1.15 ml) were incorporated into the gel mix. Aliquots (1 ml) of the collagen mixture were then pipetted into each well of a six-well plate (Becton Dickinson, Lincoln Park, NJ) and allowed to polymerize at 37°C. After polymerization, four to five retinal explants were placed into each well and overlaid with a second aliquot of the gel mix (1 ml). GMEM (1 ml) containing 5 mM glucose, 10% FBS, and varying concentrations of the peptides was added, and the explants were incubated for 8 to 11 days. Medium was changed every 3 to 4 days. A phase-contrast microscope was used to count the number of outgrowths for each explant each day. The degree of inhibition in the TSP-1–or peptide-treated cultures was reported on the day that the maximal endothelial outgrowth was observed in the control cultures (no inhibitor, 10% FBS). This method of reporting results of the explant cultures controlled for variability in the response of the retinal tissue in different experiments. The variability (1–2 days) in the time that the maximal number of outgrowths was observed in control cultures of different experiments could have been due to variability in the age of the retinal tissue obtained from the abattoir, to the handling of the retinal tissue, or to the response of the tissue to the growth factors present in the culture medium.

In experiments to study the toxicity and turnover of peptides, medium containing the peptides was replaced on day 7 with GMEM containing 5 mM glucose and 10% FBS but no peptide. The explants were further incubated until day 11, and outgrowths were counted again. For some experiments, outgrowth was also expressed semiquantitatively as clock hours. The circumference of the explant was divided into 12 quadrants, and each quadrant was scored as positive if any retinal outgrowth was present in that quadrant. This analysis yielded values from 0 (no outgrowth) to 12 (outgrowth in every quadrant). Masked assessments were conducted by three independent observers whose scores were averaged for each explant. Statistical significance was determined using the Kruskal–Wallis test,29 a nonparametric test that does not assume a normal distribution of the data and is designed to evaluate the significance of data in a rank-order format. The clock hour and explant data presented in this study are in such a format.

Rat Model of Retinopathy of Prematurity
The effects of TSP-1 and peptides on retinal neovascularization were determined using a previously described rat model.30 31 32 33 All animal experiments were performed with the highest standards of care and conformed to the principles outlined in the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. At birth, litters of Sprague–Dawley rats and their mothers were placed in a variable oxygen environment (cycles of 24 hours, 50% oxygen followed by 24 hours, 10% oxygen). The 10% oxygen atmosphere was produced by mixing appropriate fractions of pure nitrogen and room air. These oxygen levels were chosen because they produce blood oxygen tensions in the rat pups similar to those measured in infants in whom ROP develops.30 The oxygen level was alternated between 50% and 10% every 24 hours for 14 days (Fig. 2) , the time required for room air–raised rats to complete retinal vascular formation. On day 14, animals were brought into room air, randomized, and injected intravitreally with the test agent (Fig. 2) . Platelet-purified human TSP-1 (125 ng in 5 µl, 0.76 picomoles of TSP subunit) was injected on day 14 or 17. Polysucrose (70 kDa) or polysucrose-conjugated peptides were dissolved in physiological saline (at a final concentration of 750 µM as peptide), filter sterilized, and further diluted with physiological saline. A volume of 5 µl (3.75, 1.25, or 0.35 nanomoles per eye) was injected on day 14, and animals were killed on day 20. Abnormal neovascularization was assessed on day 20 by histochemically staining retinas for ADPase activity,34 a procedure that preferentially stains retinal vascular endothelium and microglia in rats of this age.31 Stained retinas were flattened on microscope slides using four radial cuts, marked for orientation of the superior quadrant, coverslipped in GelMount (Biomeda, Foster City, CA), and digitized using a digitizing camera (CCO-72; Dage-MTI, Michigan City, IN) and image analysis software (ImageGrabber ver. 2.0; Neotech, Hampshire, UK).



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. Oxygen exposure paradigm for rat ROP model. Diagram shows typical oxygen exposure. The litters of newborn rats were placed in an exposure chamber within 4 hours after birth, and the oxygen level was adjusted every 24 hours thereafter. Animals were removed to room air 14 days after birth and injected intravitreally with TSP, TSP peptides, or vehicle on day 14 (arrow 1). For some experiments, animals were injected with TSP or vehicle (arrow 2) 3 days after removal from the exposure chamber. All animals were killed (Sac) on day 20.

 
Normal vascular growth in the developing rat retinas was quantified by measuring vascular area. Retinal areas containing blood vessels were traced on the computer monitor face with an interactive stylus pen (FT Data Systems, Stanton, CA). The operator was masked to the treatment group from which each retina was derived. The area within the trace was calculated with image analysis software (Enhance 3.0; MicroFrontier, Des Moines, IA) and is reported in square millimeters. The degree of vascular disease was assessed using clock hours. A theoretical clock face was superimposed on the retinas with areas between separated quadrants omitted from the assessment. Each clock hour that was occupied by neovascular growth was counted, yielding a semiquantitative measure of severity, with values ranging from 0 (no disease) to 12 (most severe). In this context, neovascular growth included any preretinal growth and any regions of dense arterial budding within the superficial vessel plexus, with determinations confirmed at x400 magnification. Neither of these two features is observed during normal vasculogenesis in room air–raised rats. Although not rigorously quantitative, this method was chosen because it has a clear corollary in the clinical classification of ROP and is widely published by laboratories that use ROP animal models.31 35 36 37 38 39 Multiple transverse sections were impractical for the samples sizes required by this study; in addition, because of the asymmetry of the disease, such sections are prone to sampling errors. In other studies, when these sampling errors were controlled by serially sectioning entire eyes in a similar ROP model, the number of preretinal nuclei was highly correlated with clock hour measures.40 Masked assessments were conducted by three independent observers; the median of these individual assessments is reported. Statistical significance was determined by a Kruskal–Wallis test, with a Fisher’s post hoc analysis.29


   Results
Top
 Abstract
 Introduction
 Methods
 Results
Discussion
 References
 
Dose- and Time-Dependent Inhibition of Retinal Neovascularization by Platelet-Derived TSP
A newborn rat model of ROP was used to assess the antiangiogenic effects of platelet-derived TSP-1.41 Preliminary experiments indicated that TSP-1, when injected immediately after the rats had been transferred to room air, caused a dose-dependent decrease in retinal neovascularization. Maximal response was observed when between 75 and 750 ng of TSP-1 was injected per eye (data not shown), and 125 ng/eye (0.76 picomoles TSP-1 subunit per eye) was chosen as the dose for subsequent experiments. Figure 3 shows representative retinas from 20-day-old rats that were subjected to 14 days of alternating oxygen tension and then maintained in room air for an additional 6 days. The left side of the figure presents a retina from an animal injected with vehicle (PBS) immediately after return to room air. The retina exhibited severe abnormal neovascularization, including the growth of many discrete vascular tufts immediately posterior to the advancing front of vessel formation (Fig. 3 , left, arrowheads). The right side of the figure shows the contralateral retina from the same rat. This eye was injected with 0.76 picomoles TSP-1 immediately after removal from the exposure chamber. Although some abnormal neovascularization was observed, overall, this retina exhibited fewer vascular tufts than retinas from vehicle-injected eyes. Retinas from animals injected with TSP-1 3 days after return to room air had an appearance that was intermediate between that of vehicle-injected eyes and eyes injected with TSP-1 immediately after removal from the exposure chamber (data not shown).



View larger version (50K):
[in this window]
[in a new window]
  		Figure 3. Effect of TSP-1 on rat retina. Left: Flat-mounted, ADPase-stained retina from animal injected with PBS vehicle; right: retina from contralateral eye of the same rat injected with 0.76 picomoles TSP-1. Both eyes were injected on day 14, immediately after removal from the exposure chamber. Arrowheads: preretinal vascular tufts.

 
The severity of abnormal neovascularization in untreated retinas and those injected with TSP-1 or vehicle alone was quantified as shown in Figure 4A . Injection of PBS immediately after transferring the rats to room air caused a small but significant (P = 0.0106) decrease in retinal neovascularization., when platelet-derived TSP-1 was injected immediately after the animals were removed from the exposure chamber, however, neovascularization was reduced by 48% compared with the vehicle-injected control (P < 0.0001). If the injection of TSP was delayed for 3 days after transfer of the animals to room air, it had less inhibitory effect on the neovascularization response (29% inhibition, P = 0.0435, compared with the vehicle-injected control). Injection of TSP or PBS did not significantly alter normal intraretinal vessel development (vasculogenesis) at either time of injection, as shown in Figure 4B .



View larger version (49K):
[in this window]
[in a new window]
  		Figure 4. Effect of TSP-1 on retinal angiogenesis. (A) Pathologic neovascularization, expressed as clock hours, in control eyes (no inj) and in eyes that received PBS injection immediately (Veh,14/0) or 3 days (Veh,14/3) after removal from the exposure chamber, and in eyes that received 0.76 picomoles platelet-derived TSP (as subunit) immediately (TSP,14/0) or 3 days (TSP,14/3) after removal from the exposure chamber. Animals were killed on day 20. (•), Median of three or four individual assessments of each retina; ({square}), mean for each treatment group; error bars, SD; arrowhead: median. Statistical analysis was performed by Kruskal–Wallis test.29 Significantly different (+P = 0.0106 and < 0.0001 for Veh,14/0 and Veh,14/3, respectively) from noninjected control. TSP-injected retinas were compared with the appropriate vehicle-injected control **P < 0.0001; *P = 0.0435. (B) Degree of normal retinal vasculogenesis in eyes treated as described in (A). Error bars, SD. No significant differences in vascular area were observed.

 
Inhibition of Angiogenesis in a Retinal Explant Assay by TSP-1 and Synthetic Peptides Derived from the Type 1 Repeats
A retinal explant assay was used to evaluate the relative potency of intact TSP-1 and three synthetic peptides derived from the type 1 repeats of TSP-1. This assay is based on the outgrowth of endothelial cells from retinal tissue into a collagen gel.28 When intact TSP-1 was tested in this assay, low concentrations of TSP-1 (1.5 nM) slightly stimulated endothelial outgrowth, whereas higher concentrations (15 and 150 nM) significantly decreased endothelial outgrowth when compared with a serum-stimulated positive control (data not shown). The antiangiogenic properties of the TSP-1 molecule were further examined using synthetic peptides derived from the second type I repeat of TSP (Fig. 1) . Four peptides were initially tested for their ability to inhibit endothelial cell outgrowth in the retinal explant model (Table 1) . Peptide 388 (KRFKQDGGASHASPASS) contained the KRFK sequence previously reported to activate latent TGF-ß1,17 peptide 450 (KRAKAAGGWSHWSPWSSC) contained the GWXXWSPW sequence required for maximal heparin binding,20 and peptide 246 (KRFKQDGGWSHWSPWSS) derived from the native sequence of TSP-1,25 contained both the heparin-binding and TGF-ß1–activating sequences. Peptide 300 (GGWSHW) contained the minimal-consensus heparin-binding WSXW sequence; however, previous studies have shown that this sequence binds very weakly to heparin compared with peptides containing the WSPW sequence, and peptide 300 was used as a nonreactive control in the present experiments.20 Incubation of retinal explants in medium containing 10% FBS or 10% FBS and peptide 300 at 200 µM yielded cultures of identical appearance, with many retinal vascular outgrowths (>30, data not shown). In subsequent experiments, medium containing 10% FBS was used as the positive control.

Peptide 246 inhibited endothelial cell outgrowth from the retinal tissue explant in a dose-dependent fashion, as detailed in Table 2 . Between four and five explants were examined at four peptide concentrations on days 9 and 11 after the cultures were established. In the absence of the inhibitory peptide, the growth factors in the culture medium stimulated exuberant endothelial cell outgrowth (see photomicrograph in Fig. 5A ) in four of five of the explants by 9 days of culture and in five of five explants after 11 days in culture. Because of the three-dimensional nature of the explant cultures, an accurate count of endothelial sprouts from the explanted retinal tissue was very difficult to perform when the response was robust, and explants with more than 30 outgrowths were denoted as "more than 30." The data in Table 2 was representative of three independent experiments with peptide 246 (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 2. Effect of Peptide 246 on Endothelial Cell Outgrowth from Retinal Explants

 


View larger version (87K):
[in this window]
[in a new window]
  		Figure 5. Retinal explant assay for antiangiogenic activity. Discs from bovine retinas (R) were sandwiched between type I collagen gels and overlaid with GMEM containing various test agents. (A) Positive control with 10% FBS; (B) 10% FBS and 200 µM peptide 246; (C) 10% FBS and 200 µM peptide 388. Photomicrographs were taken on day 8; magnification, x160.

 
Peptide 246 was a potent inhibitor, significantly (P < 0.01) inhibiting outgrowth at 100 and 200 µM (see Table 2 and photomicrograph in Fig. 5B ). When peptide 246 was withdrawn from the cultures, explants initially maintained in 100 and 200 µM peptide, which had previously shown minimal endothelial cell sprouting, started to form tube-like structures (see day 11 data in Table 2 ). These data suggest that peptide 246 inhibited endothelial cell sprouting without irreversibly damaging the cellular machinery required for the outgrowth response. Peptides 388 and 450 were less active than 246 in inhibiting endothelial cell outgrowth, as shown in Table 3 . These data are representative of three independent experiments (data not shown). Peptide 388, which contained the TGF-ß1 activating sequence, reduced the number of outgrowths to less than 10 per explant at the highest concentration tested (200 µM, P < 0.01; Fig. 5C ). Peptide 450 at 100 µM significantly reduced (P = 0.05) the response in the explant assay. It reduced the number of outgrowths on three of five explants to less than 10 per explant. Two of the explants showed no outgrowth when treated with 100 µM of peptide 450. At the highest concentration tested (200 µM), there was a total inhibition of vascular outgrowth (P < 0.01, see Table 3 ).


View this table:
[in this window]
[in a new window]
  		Table 3. Effect of Peptides 388 and 450 on Endothelial Cell Outgrowth from Retinal Explants

 
The recovery of the endothelial proliferative response when the peptides were withdrawn from the explant cultures (Table 2) suggested that something in retinal explant cultures might be inactivating these peptide inhibitors. The D-reverse analogues of the peptides and their polysucrose conjugates are more resistant to proteases than the L-forward peptides, and have previously been shown to have enhanced inhibitory activity in cell cultures and mouse xenograft assays.26 27 The potency of D-reverse analogues and their respective polysucrose conjugates was therefore compared with that of the L-forward peptides, as shown in Figure 6 . Potency was more readily compared in the retinal explant assays when assay response was reported as clock hours of endothelial outgrowth. In this analysis, each one twelfth of the explant circumference was examined for endothelial outgrowth and scored as positive if any outgrowth occurred in that quadrant, as shown in Figure 6 . As previously noted, peptide 246 at a concentration of 100 µM almost completely inhibited endothelial outgrowth in the retinal explant assay (Fig. 6A) . When peptide 416 (the D-reverse analogue of 246) was tested at a concentration of 25 µM, two of four explants showed some endothelial outgrowth; peptide 416 at a concentration of 50 µM showed a pattern of response identical with that of peptide 246 at 100 µM. Addition of 100 µM peptide 450 produced a pattern of endothelial outgrowth similar to that observed in previous experiments (Table 3) , and the inhibition observed with 50 µM of the D-reverse analogue of 450 (peptide 476) was not significantly different. We estimate from these data that the D-reverse analogues of 246 and 450 were approximately twice as potent as the L-forward peptides in the retinal explant assay.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 6. Comparisons of the potency of L-forward peptides, D-reverse peptides, and D-reverse polysucrose-conjugated peptides in the retinal explant assay. Each one twelfth of the explant circumference was examined for endothelial cell outgrowth and scored as positive if any outgrowth occurred in that quadrant. (•), Individual datum for each explant; (+), the mean. (A) Comparison of the activities of L-forward and D-reverse peptides with heparin-binding activity (peptides 450 and 476, respectively) and with both heparin-binding and TGF-ß1–activating activity (peptides 246 and 416, respectively); (B) potency of the L-forward peptide 246 was compared with the D-reverse polysucrose-conjugated analogue with both heparin-binding and TGF-ß1 activating activity or the analogue with only heparin-binding activity (peptides 416F70 and 476F70, respectively).

 
The potency of the D-reverse polysucrose-conjugated analogue of peptide 246 and 450 were also tested (Fig. 6B) ; the D-reverse polysucrose-conjugated 246 analogue (416F70) was estimated to be approximately 40 times more potent than the corresponding L-forward peptide. Conjugation to polysucrose had a lesser effect on the potency of the conjugated heparin-binding peptide (476F70). At concentrations of 1 and 5 µM, these peptides did not significantly inhibit endothelial cell outgrowth in the explant assay.

Inhibition of Retinal Angiogenesis in the Rat Model of ROP by Synthetic Peptides Derived from TSP
For in vivo experiments, the D-reverse polysucrose-conjugated analogues of the peptides tested were used to reduce inactivation and clearance from the vitreous. Three peptide–polysucrose conjugates were tested in these studies (Table 1) ; peptide 475F70, a D-reverse analogue with the TGF-ß1 activation sequence; peptide 476F70, an analogue with heparin-binding activity; and peptide 416F70, an analogue with both activities. The peptides were conjugated to polysucrose with a molecular weight of 70 kDa. Polysucrose (70 kDa) at a concentration equivalent to that in the peptide–polysucrose conjugates was used as the vehicle control.

Inhibitory action of the peptides on retinal neovascularization is summarized in Figure 7A . Those eyes receiving no injection had significantly more vascular disease (P = 0.0351) than those injected with vehicle. Such findings are consistent with previously published results using this animal model.42 Peptide 476F70, the heparin-binding peptide with no TGF-ß1–activating activity, was the most potent antiangiogenic peptide in vivo, significantly reducing pathologic neovascularization at both concentrations tested (1.25 and 3.75 nanomoles per eye, P = 0.0117 and 0.0003, respectively). Peptide 416F70 (which contains both heparin-binding and TGF-ß1 activating sequences) was less effective at inhibiting retinal neovascularization than equimolar concentrations of peptide 476F70 and showed statistically significant inhibition only at the highest concentration tested (3.75 nanomoles per eye, P = 0.0397). In contrast, the highest concentration of peptide 475F70, which contains only the TGF-ß1–activating sequence, significantly (P = 0.0383) enhanced neovascularization when compared with vehicle-injected control eyes. At the lower concentration of 475F70, there was no difference in neovascularization compared with the vehicle control. As shown for TSP, the injected peptides had no significant effect on normal intraretinal vessel development (vasculogenesis data shown in Fig. 7B ). The morphologic differences among eyes injected with peptide 416F70 (Fig. 8 , left), peptide 476F70 (Fig. 8 middle), or 457F70 (Fig. 8 right) mirrored the results of the more quantitative data presented in Figure 7A .



View larger version (55K):
[in this window]
[in a new window]
  		Figure 7. Effect of D-reverse polysucrose-conjugated TSP-1 peptides on retinal angiogenesis in rat ROP model. (A) Pathologic neovascularization, expressed as clock hours. On day 14 of the treatment regimen, rats were placed in room air and injected intravitreally with a single 5-µl injection of the D-reverse polysucrose-conjugated peptides at concentrations of 750, 250, and 75 µM for peptide 416F70 (3.75, 1.25, or 0.38 nanomoles/eye), or 750 and 250 µM (3.75 and 1.25 nanomoles/eye) for peptides 475F70 and 476F70. The polysucrose vehicle was injected at a concentration equivalent to that in the 750 µM sample. Some eyes received no injections. (•), Median of three or four individual assessments of each retina; ({square}), mean for each treatment group; error bars, SD; arrowhead: median. Statistical analysis was performed by Kruskal–Wallis test.29 Vehicle-injected eye was significantly different (+P = 0.0351) from noninjected control. Retinas injected with conjugated peptides were compared with the vehicle-injected control: *0.01 < P < 0.05; **P < 0.01. (B) Normal retinal vasculogenesis, expressed as vascular area. No significant differences in vascular area were observed.

 


View larger version (39K):
[in this window]
[in a new window]
  		Figure 8. Effect of TSP-1 peptides on rat retinas. Shown are flat-mounted ADPase-stained retinas from eyes injected with (left) 3.75 nanomoles peptide 416F70, (middle) 3.75 nanomoles peptide 476F70, (right) 3.75 nanomoles peptide 475F70. Refer to Figure 3 (left) for vehicle effect. Arrowheads: Preretinal vascular tufts.

 

   Discussion
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
References
 
There is growing evidence for the role of TSP-1 in inhibition of angiogenesis both in vitro and in vivo.10 11 12 16 43 44 45 TSP-1 has been shown to inhibit FGF-2–induced migration and growth in bovine aortic endothelial cells,18 reduce angiogenesis in transfected cell lines,12 46 and inhibit rat corneal neovascularization, independent of TGF-ß activity.45 47 The reported proangiogenic action of TSP-1 appeared to be indirect and as a result of leukocyte or myofibroblast infiltration of the biological assays used.14 48

The ability of TSP-1 to suppress angiogenesis appears to reside solely in the procollagen-like domain and the second and third type 1 repeats of the molecule. Tolmsa et al.16 showed that the central 70-kDa region of TSP-1 could block angiogenesis induced by FGF-2 in the rat cornea and inhibit migration and [3H]thymidine incorporation stimulated by FGF-2 in cultured bovine adrenal capillary endothelial cells. Further studies have revealed two subdomains that appear to act independently to suppress angiogenesis: a tryptophan-rich motif that binds to heparin20 and the GVQXR motif that binds CD36.21 The second type 1 repeat of TSP-1 also contains a basic sequence KRFK that binds to and activates TGF-ß1 in vitro and in vivo.17 49 TGF-ß has been reported to be a potent inhibitor of endothelial proliferation in vitro,50 whereas it has been reported to stimulate angiogenesis in vivo.51 52

In this study, we examined the effect of TSP-1 and peptides derived from the second type 1 repeat on two models of retinal neovascularization: an in vivo model of ROP and an in vitro model of retinal endothelial cell outgrowth. Injection of 0.76 picomoles of the intact TSP-1 molecule in the rat ROP model inhibited pathologic neovascularization in the retinas of treated animals. TSP-1 was more effective in vivo when administered immediately after removal of the animals from the oxygen pressure chamber. Thus, this extracellular matrix molecule most likely inhibited an early step in the angiogenic process. Previous reports that platelet-derived TSP may be contaminated with TGF-ß1 raised concerns about the contribution of TGF-ß1 to the antiangiogenic activities of TSP. TGF-ß1 was undetectable by enzyme-linked immunosorbent assay in the platelet-purified TSP-1 used in these experiments (data not shown). Because levels in the nanogram per millimeter range are required for the suppression of endothelial cell proliferation,50 it is unlikely that the antiangiogenic responses observed with the injected TSP were due to contamination with TGF-ß1.

Peptides derived from the native sequence of TSP-1 (containing both the WSXW heparin-binding domain and the KRFK TGF-ß1 activation domain) and mutant versions in which these domains were abrogated were first tested in a bovine retinal explant assay. This model is a complex system allowing multiple cellular interactions in a three-dimensional type I collagen gel. The cells that grow out from the explant have been shown by surface markers to be of endothelial origin.28 The system also contains a large number of activated and proliferating macrophages,28 a cell type that exhibits very high levels of oxygen consumption.53 In cultures with high oxygen consumption, the rate of diffusion usually limits oxygen delivery to the explanted tissue.54 The low oxygen tensions that result from limited oxygen delivery are likely to be responsible for the tissue damage and subsequent endothelial outgrowth observed in the explanted retinal tissue.28 Peptide 246, derived from the native sequence of TSP, significantly inhibited retinal vascular outgrowth in this assay at concentrations of 100 and 200 µM. This pronounced inhibition of vascular outgrowth did not appear to be due to endothelial cell toxicity at high peptide concentrations. If the peptide in the explant cultures was not replenished, small outgrowths from explants were observed in previously inhibited cultures 4 days after the last addition of peptide (Table 2) . These data suggest that the explants had the ability to metabolize the inhibitory peptide and that cells capable of forming vascular outgrowths were still present in the cultures. The enhanced potency of the D-reverse peptides and their polysucrose conjugates in the explant assay (Fig. 6) may thus be a result of their enhanced half-life in the vicinity of the explant.

The active sequence motifs of peptide 246 (WSXW and KRFK) were further investigated using mutated versions of the peptide. Peptide 388, containing the KRFK domain responsible for activating TGF-ß1, was active only at the highest concentration tested (200 µM; Table 3 and Fig. 3B ). Peptide 450 and 476F70, which bind to heparin through tryptophan-rich sequences, were more inhibitory than peptides carrying only the KRFK sequence and inferior to the peptides carrying both sequences. Studies indicate that heparin and heparan sulfate are required for the stabilization and oligomerization of FGF-2 and VEGF that lead to receptor activation and signaling.55 56 57 58 59 60 Binding of tryptophan-rich motif to cell surface heparan sulfate proteoglycans may therefore deplete their availability for growth factor receptor binding. A heparin-binding peptide from type I collagen has recently been shown to inhibit endothelial tube formation in collagen gels, presumably by disrupting cell interactions with collagen fibrils,61 and it is possible that the heparin-binding, tryptophan-rich sequences in the current study had a similar effect. In the retinal explant assay, peptides 246, 416, and 416F70 (containing both the WSXW and KRFK sequences) were the most potent of the three peptides, possibly because of the synergism of growth factor antagonism and TGF-ß1 activation. Experiments with pure populations of vascular endothelial cells have demonstrated that peptide 246 inhibits migration and proliferation of these cells19 while increasing the rate of apoptosis.26

Onset of ischemia is one process that may initiate the cascade of events leading to retinal neovascularization, although such nonischemic conditions as acidosis and bacterial infection can also lead to new blood vessel formation.33 37 In our in vivo study, ischemia was induced by exposing newborn rats to variable hyperoxia. The D-reverse peptide analogue containing the tryptophan-rich heparin-binding sequence but without the TGF-ß1 activation sequence was most active in inhibiting neovascularization in the ROP model. In contrast, injection of the peptide containing the only the TGF-ß1 activation sequence actually stimulated the extent of pathologic neovascularization over that observed in vehicle-injected controls. The peptide with both WSXW and KRFK sequences also significantly reduced the neovascularization in the ROP model but was not as potent as the peptide containing only the heparin-binding domain. This could be due to opposing activities of the KRFK and WSXW sequences. The action of peptides in the ROP model varied significantly from that of retinal explant assay. The difference in the responses observed in the two angiogenic assays was not due solely to the use of D-reverse polysucrose-conjugated versions of these peptides in the animal model. When tested in the explant assay, these D-reverse polysucrose conjugates showed the same order of potency as the L-forward peptides (see Fig. 6B ).

The peptides used to inhibit neovascularization in the rat ROP model were polysucrose-conjugated molecules of relatively high molecular weight (>80 kDa).27 The high molecular weight of these conjugates prevented their penetration through the inner limiting membrane of the retina; the molecular weight limit for the penetration of proteins from the vitreous into the retina appears to be approximately 60 kDa.62 Because the pathologic neovascularization has infiltrated the inner limiting membrane, these vessels would be susceptible to the action of the protein and peptide inhibitors injected into the vitreous, whereas normal vasculogenesis would not. Thus, under the conditions of these experiments, both TSP and the TSP-derived peptides appear to inhibit only the neovascularization. Experiments are in progress to determine whether the size of the peptide administered intravitreously may influence the type of inhibition observed in the rat model.

In the ROP model, the heparin-binding peptide was most active in inhibiting neovascularization. Previous studies from our laboratories have shown that that peptide 246 antagonizes basic (b)FGF through binding to heparan sulfate and proteoglycans. These data include inhibition of binding of radiolabeled bFGF to endothelial cells,19 heparin,26 and heparan sulfate.63 The interaction of the peptides with cells is inhibited by heparatinase treatment.64 The essential role of heparan sulfate proteoglycans in growth factor signaling has also been extensively documented.55 56 57 58 59 60 Thus, the primary mode of inhibition by the peptides appeared to be interference in the binding and activation of heparin-binding growth factors to their receptors. Ischemia in the retina stimulates the release of VEGF and FGF-2 as a result of tissue damage or due to hypoxic induction of Müller cells and leukocytes.65 66

The variable effect of the TFG-ß1 activation domain in the two angiogenic assays may relate to the levels of latent TGF-ß1 present in the two model systems. TGF-ß1 at low levels has been shown to inhibit endothelial migration and proliferation in vitro, and low levels of TGF-ß have been reported in the vitreous of human donors without ocular complications.67 68 However, vitreoretinal diseases have been previously shown to cause a breakdown of the blood–ocular barrier,69 70 and this breakdown could subsequently lead to increased vitreous concentrations of TGF-ß1.71 72 Activation of these higher levels of TGF-ß1 by the KRFK domain of the type 1 repeats might then stimulate the angiogenic process.

TSP-1 has long been known as a natural regulator of the angiogenic process, and recent studies by Suzuki et al.73 have demonstrated that ischemic retina and VEGF-stimulated retinal neovascular cells synthesize and secrete TSP-1. The authors suggest that the VEGF-mediated induction of TSP-1 may be a negative feedback mechanism to control retinal neovascularization. In those cases in which neovascularization is not controlled by this process, the administration of peptides derived from the antiangiogenic type 1 repeats of TSP-1 may be a safe and effective therapy. In the context of the ROP model, it is notable that normal intraretinal vessel growth was unaffected by TSP-1 or peptide injection. The in vivo effectiveness of these simple peptides suggest that agents that compete with heparin-binding growth factors for cell surface heparan sulfate proteoglycans may be promising pharmacologic agents for treatment of ocular angiogenesis.


   Footnotes
 
2 Present address: Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110. Back

Supported by Research to Prevent Blindness, Wasserman Merit Award (JSP), Research to Prevent Blindness Grants to Tulane University and Vanderbilt University Departments of Ophthalmology and Visual Science, National Institutes of Health Grants EY-07533 (JSP) and EY-09092 (DAB), and Department of Defense Grant DAMD17-94-J-4499 (DDR).

Submitted for publication September 29, 1999; revised February 1, 2000; accepted February 10, 2000.

Commercial relationships policy: N.

Corresponding author: Diane A. Blake, Department of Ophthalmology, SL-69, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112. dblake{at}tmcpop.tmc.tulane.edu


   References
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. . American Academy of Ophthalmology (1987) Eye Care for the American People American Academy of Ophthalmology/NAME> San Francisco.
  2. Aiello, LP, Gardner, TW, King, GL, et al (1998) Diabetic retinopathy Diabetes Care 21,143-156[Medline][Order article via Infotrieve]
  3. Forrester, JV, Shafiee, A, Schroder, S, Knott, R, McIntosh, LC (1993) The role of growth factors in proliferative diabetic retinopathy Eye 7,276-287
  4. Tolentino, MJ, Adamis, MP (1998) Angiogenic factors in the development of diabetic iris neovascularization and retinopathy Int Ophthalmol Clin 38,77-94[Medline][Order article via Infotrieve]
  5. Robinson, GS, Aiello, LP (1998) Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow Int Ophthalmol Clin 38,89-102[Medline][Order article via Infotrieve]
  6. Adamis, AP, Shima, DT, Tolentino, MJ, et al (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114,66-71[Abstract]
  7. Aiello, LP, Pierce, EA, Foley, ED, et al (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Nat Acad Sci USA 92,10457-10461[Abstract/Free Full Text]
  8. Robinson, GS, Pierce, EA, Rook, SL, Foley, ED, Webb, R, Smith, LC (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy Proc Nat Acad Sci USA 93,4851-4856[Abstract/Free Full Text]
  9. Grant, SW, Kyshtobayeva, AS, Kurosaki, T, Jakowatz, J, Fruehauf, JP (1998) Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma Cancer Detect Prev 22,185-194[Medline][Order article via Infotrieve]
  10. Castle, VP, Dixit, VM, Polverini, PJ (1997) Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells Lab Invest 77,51-61[Medline][Order article via Infotrieve]
  11. Sheibani, N, Newman, PJ, Frazier, WA (1997) Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis Mol Biol Cell 8,1329-1341[Abstract]
  12. Weinstat–Saslow, DL, Zabrenetzky, VS, VanHoutte, K, Frazier, WA, Roberts, DD, Steeg, PS (1994) Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis Cancer Res 54,6504-6511[Abstract/Free Full Text]
  13. Nicosia, RF, Tuszynski, GP (1994) Matrix-bound thrombospondin promotes angiogenesis in vitro J Cell Biol 124,183-193[Abstract/Free Full Text]
  14. BenEzra, D, Griffin, BW, Maftzir, G, Aharonov, O. (1993) Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide Invest Ophthalmol Vis Sci 34,3601-3608[Abstract/Free Full Text]
  15. Roberts, DD (1996) Regulation of tumor growth and metastasis by thrombospondin-1 FASEB J 10,1183-1191[Abstract]
  16. Tolmsa, SS, Volpert, OV, Good, DJ, Frazier, WA, Polverini, PJ, Bouck, N. (1993) Peptides derived from two separate domains of the matrix protein thrombospondin have anti-angiogenic activity J Cell Biol 122,497-511[Abstract/Free Full Text]
  17. Schultz–Cherry, S, Chen, H, Mosher, DF, et al (1995) Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1 J Biol Chem 270,7304-7310[Abstract/Free Full Text]
  18. Taraboletti, G, Roberts, DD, Liotta, LA, Giavazzi, R. (1990) Platelet thrombospondin modulates endothelial cell adhesion, motility and growth: a potential angiogenesis regulatory factor J Cell Biol 111,765-772[Abstract/Free Full Text]
  19. Vogel, T, Guo, NH, Krutzsch, HC, et al (1993) Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin J Cell Biochem 53,74-84[Medline][Order article via Infotrieve]
  20. Guo, NH, Krutzsch, HC, Negre, E, Zabrenetzky, VS, Roberts, DD (1992) Heparin-binding peptides from the type I repeats of thrombospondin: structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis J Biol Chem 267,19349-19335[Abstract/Free Full Text]
  21. Dawson, DW, Pearce, SF, Zhong, R, Silverstein, RL, Frazier, WA, Bouck, NP (1997) CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells J Cell Biol 138,707-717[Abstract/Free Full Text]
  22. Chung, J, Gao, AG, Frazier, WA (1997) Thrombospondin acts via integrin-associated protein to activate the platelet integrin alpha IIb beta 3 J Biol Chem 272,14740-14746[Abstract/Free Full Text]
  23. Brooks, PC, Silletti, S, von Schalscha, TL, Friedlander, M, Cheresh, DA (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity Cell 92,391-400[Medline][Order article via Infotrieve]
  24. Friedlander, M, Theesfeld, CL, Sugita, M, et al (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases Proc Nat Acad Sci USA 93,9764-9769[Abstract/Free Full Text]
  25. Guo, NH, Krutzsch, HC, Negre, E, Vogel, T, Blake, DA, Roberts, DD (1992) Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion Proc Nat Acad Sci USA 89,3040-3044[Abstract/Free Full Text]
  26. Guo, N, Krutzsch, HC, Inman, JK, Roberts, DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells Cancer Res 57,1735-1742[Abstract/Free Full Text]
  27. Guo, NH, Krutzsch, HC, Inman, JK, Shannon, CS, Roberts, DD (1997) Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1 J Peptide Res 50,210-221[Medline][Order article via Infotrieve]
  28. Forrester, JV, Chapman, A, Kerr, C, Roberts, J, Lee, WR, Lackie, JM (1990) Bovine retinal explants cultured in collagen gels: a model system for the study of proliferative retinopathy Arch Ophthalmol 108,415-420[Abstract]
  29. Sheskin, DJ (1996) Handbook of Parametric and Nonparametric Statistical Procedures ,397-405 CRC Press Boca Raton, FL.
  30. Penn, JS, Henry, MM, Wall, PT, Tolman, BL (1995) The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats Invest Ophthalmol Vis Sci 36,2063-2070[Abstract/Free Full Text]
  31. Penn, JS, Henry, MM (1996) Assessing retinal neovascularization in an animal model of proliferative retinopathy Microvasc Res 51,126-130[Medline][Order article via Infotrieve]
  32. Berkowitz, BA, Penn, JS (1998) Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity Invest Ophthalmol Vis Sci 39,840-845[Abstract/Free Full Text]
  33. Robbins, SG, Rajaratnam, VS, Penn, JS (1998) Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina Growth Factors 16,1-9[Medline][Order article via Infotrieve]
  34. Flower, RW, McLeod, DS, Lutty, GA, Goldberg, B, Wajer, SD (1985) Postnatal retinal vascular development of the puppy Invest Ophthalmol Vis Sci 26,957-968[Abstract/Free Full Text]
  35. Holmes, JM, Duffner, A. (1996) The effect of growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat Curr Eye Res 15,403-409[Medline][Order article via Infotrieve]
  36. Zhang, S, Leske, DA, Uhl, JR, Cockerill, FR, Lanier, WL, Holmes, JM (1999) Retinopathy associated with Enterococcus enteropathy in the neonatal rat Invest Ophthalmol Vis Sci 40,1305-1309[Abstract/Free Full Text]
  37. Holmes, JM, Zhang, S, Leske, DA, Lanier, WL (1999) Metabolic acidosis-induced retinopathy in the neonatal rat Invest Ophthalmol Vis Sci 40,804-809[Abstract/Free Full Text]
  38. Holmes, JM, Zhang, S, Leske, DA, Lanier, WL (1997) The effect of carbon dioxide on oxygen-induced retinopathy in the neonatal rat Curr Eye Res 16,725-732[Medline][Order article via Infotrieve]
  39. Holmes, JM, Zhang, S, Leske, DA, Lanier, WL (1998) Carbon dioxide-induced retinopathy in the neonatal rat Curr Eye Res 17,608-616[Medline][Order article via Infotrieve]
  40. Zhang, S, Leske, DA, Holmes, JM (1999) Comparison of neovascularization grading methods in a rat model of retinopathy of prematurity [ARVO Abstract] Invest Ophthalmol Vis Sci 40(4),S700Abstract nr 3695
  41. Penn, J, Henry, MM, Tolman, BL (1994) Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat Pediatr Res 36,724-731[Medline][Order article via Infotrieve]
  42. Niesman, MR, Johnson, KA, Penn, JS (1997) Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity Neurochem Res 22,597-605[Medline][Order article via Infotrieve]
  43. Hugo, C, Pichler, RP, Schultze–Lohoff, E, et al (1999) Thrombospondin-peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo in experimental mesangial proliferative glomerulonephritis in the rat Kidney Int 55,2236-2249[Medline][Order article via Infotrieve]
  44. Sheibani, N, Frazier, WA (1998) Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype Mol Biol Cell 9,701-713[Abstract/Free Full Text]
  45. Campbell, SC, Volpert, OV, Ivanovich, M, Bouck, NP (1998) Molecular mediators of angiogenesis in bladder cancer Cancer Res 58,1298-1304[Abstract/Free Full Text]
  46. Sheibani, N, Frazier, WA (1995) Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis Proc Nat Acad Sci USA 92,6788-6792[Abstract/Free Full Text]
  47. Hsu, SC, Volpert, OV, Steck, PA, et al (1996) Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1 Cancer Res 56,5684-5691[Abstract/Free Full Text]
  48. Tuszynski, GP, Nicosia, RF (1996) The role of thrombospondin-1 in tumor progression and angiogenesis Bioessays 18,71-76[Medline][Order article via Infotrieve]
  49. Crawford, SE, Stellmach, V, Murphy–Ullrich, JE, et al (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo Cell 93,1159-1170[Medline][Order article via Infotrieve]
  50. Baird, A, Durkin, T. (1986) Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors Biochem Biophys Res Commun 138,476-482[Medline][Order article via Infotrieve]
  51. Iruela–Arispe, ML, Sage, EH (1993) Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-beta 1 J Cell Biochem 52,414-430[Medline][Order article via Infotrieve]
  52. Roberts, AB, Sporn, MB, Assoian, RK, et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro Proc Nat Acad Sci USA 83,4167-4171[Abstract/Free Full Text]
  53. Karnofsky, MA, Badwey, JA (1986) Respiratory burst during phagocytosis: An overview Methods Enzymol 132,353-354[Medline][Order article via Infotrieve]
  54. Muller–Kliesser, WF, Sutherland, RM (1982) Influence of convection in the growth medium on oxygen tensions in multicellular spheroids Cancer Res 42,237-242[Abstract/Free Full Text]
  55. Lam, K, Rao, VS, Qasba, PK (1998) Molecular modeling studies on binding of bFGF to heparin and its receptor FGFR1 J Biomol Struct Dyn 15,1009-1027[Medline][Order article via Infotrieve]
  56. Colin, S, Jeanny, JC, Mascarelli, F, et al (1999) In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor Mol Pharmacol 55,74-82[Abstract/Free Full Text]
  57. Sperinde, GV, Nugent, MA (1998) Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells Biochemistry 37,13153-13164[Medline][Order article via Infotrieve]
  58. Doughtier, AM, Wasserstrom, H, Torley, L, et al (1997) Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor Growth Factors 14,257-268[Medline][Order article via Infotrieve]
  59. Faham, S, Hileman, RE, Fromm, JR, et al (1996) Heparin structure and interactions with basic fibroblast growth factor Science 271,1116-1120[Abstract]
  60. Waksman, G, Herr, AB (1998) New insights into heparin-induced FGF oligomerization Nat Struct Biol 5,527-530[Medline][Order article via Infotrieve]
  61. Sweeney, SM, Guy, CA, Fields, GB, San, Antonio JD (1998) Defining the domains of type I collagen involved in heparin-binding and endothelial tube formation Proc Nat Acad Sci USA 95,7275-7280[Abstract/Free Full Text]
  62. Maurice, DM, Mishima, S. (1984) Ocular pharmacokinetics. Ocul Pharmacol 69,20-107 Springer–Verlag Berlin.
  63. Yu, H, Tyrell, D, Cashel, J, et al (2000) Specificities of heparin-binding sites from the amino terminus and type I repeats of thrombospondin-1 Arch Biochem Biophys 374,13-23[Medline][Order article via Infotrieve]
  64. Sipes, JM, Krutzsch, HC, Lawler, J, Roberts, DD (1999) Cooperation between thrombospondin-1 type 1 repeat peptides and alpha (v) beta (3) integrin ligands to promote melanoma spreading and focal adhesion kinase phosphorylation J Biol Chem 274,22755-22762[Abstract/Free Full Text]
  65. Miller, JW, Adamis, AP, Aiello, LP (1997) Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy Diabetes Metab Rev 13,37-50[Medline][Order article via Infotrieve]
  66. Idiom, K, Yoshikawa, N, Connolly, DT, Nakamura, H. (1993) Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor Kidney Int 44,959-966[Medline][Order article via Infotrieve]
  67. Lute, GA, Merges, C, Threlkeld, AB, Crone, S, McLeod, DS (1993) Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid Invest Ophthalmol Vis Sci 34,477-487[Abstract/Free Full Text]
  68. Pascal, LR, Dorman–Pease, ME, Lutty, GA, Quigley, HA, Jampel, HD (1993) Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye Invest Ophthalmol Vis Sci 34,23-30[Abstract/Free Full Text]
  69. Sjostrand, J, Karlsson, JO, Andersson, AK (1992) Changes in the soluble protein of the human vitreous in vitreoretinal disease Acta Ophthalmol 70,814-819
  70. Clausen, R, Weller, M, Wiedemann, P, et al (1991) An immunochemical quantitative analysis of the protein pattern in physiologic and pathologic vitreous Graefes Arch Clin Exp Ophthalmol 229,186-190[Medline][Order article via Infotrieve]
  71. Kon, CH, Occleston, NL, Aylward, GW, Khaw, PT (1999) Expression of vitreous cytokines in proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 40,705-712[Abstract]
  72. Hirase, K, Ikeda, T, Sotozono, C, et al (1998) Transforming growth factor beta 2 in the vitreous of proliferative diabetic retinopathy Arch Ophthalmol 116,738-741[Abstract/Free Full Text]
  73. Suzuki, K, Takagi, H, Otani, A, Oh, H, Honda, Y. (1999) Expression of thrombospondin-1 in ischemia-induced retinal neovascularization Am J Pathol 154,343-354[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 IOVSHome page
P. G. Sreekumar, J. Zhou, J. Sohn, C. Spee, S. J. Ryan, B. J. Maurer, R. Kannan, and D. R. Hinton
N-(4-hydroxyphenyl) Retinamide Augments Laser-Induced Choroidal Neovascularization in Mice
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1210 - 1220.
[Abstract] [Full Text] [PDF]

Home page